The current tuberculosis (TB) treatment landscape has been studied extensively, but research ers rarely consider how it creates challenges or opportunities for future regimen change.
B A C K G R O U N D :
The current tuberculosis (TB) treatment landscape has been studied extensively, but research ers rarely consider how it creates challenges or opportunities for future regimen change.
M E T H O D S :
In 166 stakeholder interviews in the TB high-burden countries (HBCs), we investigated areas of fi rst-line TB treatment and control that would affect, and be affected by, a future TB regimen change. Responses were compared with existing standardized data. R E S U LT S : Public sector regimens are converging towards a single standard, which facilitates comparison with a single control arm from clinical trials. However, fi nal product design is challenging if the goal is fi xeddose combinations and patient kits, whose current widespread use addresses continuing weaknesses in drug management. Any product must address broad groups, as relatively low levels of drug susceptibility testing (DST) do not allow for individualized therapy. Finally, the protection of new drugs from the development of resistance will be challenging, as the implementation of directly observed therapy and public-private mix programs is incomplete, and substantial private sectors have been identifi ed as early adopters of these drugs.
C O N C L U S I O N S :
Health systems for TB treatment and control must be improved not only to allow better implementation of current treatments but also to set the stage for implementation of new, improved TB regimens.
K E Y W O R D S : regimen change; tuberculosis drugs; highburden countries
A NEW TUBERCULOSIS (TB) regimen must compete with current regimens 1 based on clinical trial evidence, but it must also fi t into the existing health system. 2 Here, we quantify certain parameters of the existing TB treatment landscape and investigate how this landscape would impact the introduction of a new TB regimen.
Within the DOTS approach, a key variable is the choice of regimen by the National TB Program (NTP). These choices have at times been controversial; 3 conservative approaches with the current fi rst-line drugs have been common due to the paucity of alternative drug options. More recently, an increase in the evidence base has helped to fi ne-tune World Health Organization (WHO) recommendations regarding regimen choice. [4] [5] [6] The limited capacity for drug susceptibility testing (DST) in the high-burden countries (HBCs) 7 has not allowed for individualized regimens.
Adherence to the regimen is maximized by delivering TB drugs with directly observed treatment (DOT). 8 Variants of this approach include facility-based or community-based DOT, with observation by health workers, community health workers, or family members. 9 As the optimal strategy depends on context, more recently the emphasis has been on taking a patientcentered approach. 10 A new regimen would need to fi t into TB drug delivery systems that have been simplifi ed over the past two decades. Two leading approaches to minimize problems with weak drug management have been the use of fi xed-dose combinations (FDCs) 11 and patient kits. A single patient kit holds an entire 6-or 8-month regimen for a patient; the kits ensure that drugs do not run out mid-regimen, simplify drug quantifi cation, and help patients to understand that the regimen is lengthy, for a fi xed term, and requires commitment.
Public-private mix (PPM) programs allow the public sector to monitor and infl uence the regimens used in the private sector, via activities such as supervision, referral and provision of standardized drugs; they were devised in recognition of the substantial private sector involvement in TB care. 12 Scaled-up PPM interventions are cost-effective, 13 but PPM programs have faced challenges. 14 The new regimen that may enter this landscape in 15 Planning for global regimen change requires greater knowledge about the extent of certain key practices that will affect, and be affected by, regimen change. This article provides such a quantitative overview, and identifi es a number of action points that will strengthen delivery of both current and future regimens.
METHODS
While investigating past regimen changes, 11 we surveyed stakeholders about TB health system issues related to regimen change. The countries included in the study are the 22 defi ned by the WHO as HBCs for TB, and the majority of our questions were on public sector policies, given the importance of the public sector in TB control (although some questions on the private sector were included). The primary focus was on the delivery of treatment for drug-susceptible TB, as treatments for multidrug-resistant TB (MDR-TB) have very different fi nancial and human resource requirements.
From April to August 2008, data were collected by conducting 166 stakeholder interviews in 21 countries, as described 11 (inquires were restricted to e-mail for Myanmar due to Cyclone Nargis). No ethics committee was involved, as the unit of inquiry was held to be institutions (and their behavior) rather than i ndividuals. Informed consent was obtained verbally using a standard script; interviewees agreed that it was 'OK to summarize your comments, without specifi c attribution to you or your institution, for inclusion in a public report.' Any documents that associated an individual with a response were restricted to the study team, who had signed confi dentiality agreements. Before public release of data, responses were combined and anonymized. The substantial number of respondents per country ensured continued anonymity.
Each interviewer (one per country, each a professional in the fi eld of TB drug management) was trained by phone using a standardized information packet and training presentation. Interviewees were identifi ed by a combination of purposive sampling and snowball sampling, as in previous studies of public sector regimen decision-making. 1, 2 Each interviewer identifi ed, in collaboration with the central study team, an initial set of three key interviewees-one each from the NTP, the WHO country offi ce, and the regulatory authority. These and subsequent interviewees were asked to identify other key individuals and organizations involved in TB health systems and TB regimen decision making.
Interview topics were identifi ed by considering all the regimen change steps outlined by the Stop TB Partnership's Retooling Taskforce 16 and the concerns previously raised by stakeholders regarding new TB regimens. 1 We considered the following as relevant to regimen change: which TB drugs are used (public sector regimens, FDC use, regimen choice in the private sector); how TB drugs are delivered (NTP performance, drug management performance, how DOT is practiced, size of TB private sector, extent of PPM programs); and how the continued effi cacy of drugs is ensured (extent of DST, and FDC and DOT issues mentioned above). As there are two fl uoroquinolones in Phase III trials for drug-susceptible TB, we asked about the availability of fl uoroquinolones and of data on fl uoroquinolone resistance.
Interviewees were asked to respond 'to the best of [their] knowledge'. Answers from different interviewees were cross-checked and, where possible, the data collected were compared to WHO data. 17 If stakeholders made a qualitative observation, the observation is noted in the text followed by the names of the stakeholders' countries in parentheses. These observations were elaborations from the questions originally asked, so were only detected in the countries noted.
RESULTS

Public sector regimens
In the public sector, the current regimen provides the baseline against which any new regimen will be judged. Although WHO guidelines have allowed for some variation in treatment regimens for drug-susceptible TB, we found that globally these regimens in HBCs ( ‡ Daily for those with HIV/AIDS, and daily being phased in for other patients. § Committed to daily 2HRZE/4HR after our interview period concluded. HBC = high-burden country; H = isoniazid; R = rifampicin; Z = pyrazinamide; E = ethambutol; S = streptomycin. Numbers before the letters indicate the duration in months of the phase of treatment; HIV = human immunodefi ciency virus; AIDS = acquired immune-defi ciency syndrome.
s ingle standard of daily 2HRZE/4HR (true for 13/22 HBCs). These data are in agreement with WHO data, 17 with the exception of a recent regimen change by Bangladesh. After our interviews were completed, Uganda and Viet Nam also committed to the 6-month regimen. Weight band information for adult (>30 kg) Category I patients (i.e., new smear-positive or serious smear-negative cases) was available for 12 HBCs (Table 3). Exact cut-offs for weight bands differ between countries but, more importantly, so do the number of weight bands. Of the 12 HBCs, only half used four weight bands. Thus, some HBCs do not dose entirely within the recommended range of 8-12 mg/kg of rifampicin.
Variants on the standard regimen
Stakeholders were asked if there were any variants on the standard Category I regimens. The two main categories of regimen variants mentioned were 'overtreatment' (the addition of extra drugs to 'ensure a cure') and the beginning of a regimen change (see private sector section below). Overtreatment reportedly arises because physicians are faced with rising drug resistance and inadequate DST capacity; distrust in drug quality was also mentioned by one stakeholder. Their solution is often the addition of a single drug, usually a fl uoroquinolone, even though this may be the only new, active drug in an otherwise failing TB regimen (Indonesia, Philippines, and Thailand for Category I; China and Russian Federation for Category II).
Use of fi xed-dose combinations
A critical component of the TB treatment landscape is the use of quality-assured FDCs. Current use of FDCs by NTPs was reported ( Figure) as being more widespread than indicated by WHO data. 17 Stakeholders reported that NTPs in 20/22 HBCs use a twodrug FDC, usually for the continuation phase. The remaining two countries are China, which is piloting both two-and four-drug FDCs, and India, which is the only HBC NTP with no use or plans for use of FDCs. Both China and India use co-blistered drugs as an alternative to FDCs.
Stakeholders also stated that 18 of the 20 HBC NTPs that were using a two-drug FDC were also currently using a four-drug FDC. The two that were not were Brazil, which had fi rm plans to adopt a fourdrug FDC in 2009, and Viet Nam, which reportedly Figure Number of HBCs using 2-and 4-FDCs. HBC = highburden country; FDC = fi xed-dose combination. In 12 HBCs it was clear that loose drugs were only available in very limited amounts (e.g., for side-effect management), suggesting that FDCs were the primary dosing formulation used by NTPs in these countries. Of the remaining countries, two (India and China) use few or no FDCs, and seven yielded responses that were unclear. Only in Thailand was it stated that providers could choose whether they used loose drugs or FDCs.
The Global Drug Facility (GDF) supplies eight different adult and pediatric FDCs. Five additional FDCs were available in at least one HBC other than the Russian Federation; the latter country had 14 additional, unique formulations.
Patient kits and drug management
Although we did not ask about packaging, the use or adoption of patient kits in the country was mentioned by stakeholders in Kenya, Myanmar, Nigeria (adoption initiated) and Viet Nam (adoption desired but not yet initiated). The GDF reported that, in at least one of the last 3 years, they have supplied patient kits to 23 countries (including 6 HBCs, namely Afghanistan, Indonesia, Kenya, Myanmar, Nigeria and the Philippines; T Moore, GDF, personal communication based on GDF database). In addition, India and South Africa supply their own kits. These 8 HBCs represent 42% of the worldwide burden of smear-positive TB. 17 When asked about strengths and weaknesses of drug management, stakeholders mentioned significant issues with TB drug stock-outs in 7 HBCs (Cambodia, China, Democratic Republic [DR] of Congo, Kenya, Pakistan, South Africa and Uganda), TB drug expiries in 2 HBCs (Ethiopia and Tanzania) and both stock-outs and expiries in 4 HBCs (Indonesia, Mozambique, Nigeria and Zimbabwe). Seven of these HBCs fi gure amongst the 11 HBCs previously reporting stock-outs of fi rst-line drugs at either central or peripheral locations. 17 Extent of drug susceptibility testing Stakeholders stated that eight HBCs conduct no testing for fl uoroquinolone resistance in the public sector outside of a clinical trial setting. Another 8 HBCs test some MDR-TB patients and/or retreatment patients for fl uoroquinolone resistance, but often at one or very few treatment centers. Widespread testing for fl uoroquinolone resistance was claimed only in the Russian Federation and was planned for the future in Brazil (DST capacity not determined in four HBCs).
The WHO reports that 9 HBCs have access to secondline DST either within or outside the country. 17 This lack of fl uoroquinolone DST contrasts with the widespread availability of fl uoroquinolones, which are used for a number of non-TB indications. Stakeholders stated that fl uoroquinolones require a prescription in 18 HBCs (none required in 2 HBCs; status unknown in 2 HBCs), and yet they are available over the counter in 15 HBCs (mixed opinion or unclear in 5 HBCs; not available over the counter in 2 HBCs). Many respondents made it clear that fl uoroquinolones were freely and widely available in their country. Fluoroquinolones were believed to be used for fi rst-line TB treatment in the public and private sectors in the Russian Federation and in the private sector in 5 HBCs in Asia; opinions on this topic for China were mixed.
Extent of directly observed treatment
Stakeholders were asked to describe the frequency of DOT in both treatment phases and to identify the personnel conducting DOT. Due to the variability of DOT within most HBCs, answers were not always simple to interpret. However, stakeholders did mention that encounters with health care centers are often restricted to weekly, biweekly or monthly visits (Table 4) . In many HBCs, stakeholders noted that direct observation is primarily conducted by family (Indonesia, Kenya, Mozambique, Zimbabwe), self (Ethiopia, Nigeria, Russian Federation) or either family or self (China). The concept of self-DOT seems contradictory and was not an option in the interview guide; the answer is nevertheless reported because it was provided.
Private sector size and PPM coverage
The importance of the private sector in TB regimen change depends on how many TB patients access (Table 5) . TB treatment in the private sector was reported as being prohibited in Brazil and the Russian Federation, prohibited but without enforcement in Cambodia and Zimbabwe, and not prohibited in the remaining 18 HBCs. Stakeholders added that TB drug sales in the private sector are prohibited at least in Brazil, DR Congo, Ethiopia, the Russian Federation, and Zimbabwe, and TB drugs in Tanzania are restricted to the public sector via importation controls.
The infl uence of PPM programs depends on their size. Stakeholders were asked about the number of patients and physicians in PPM programs. Up to 9 HBCs reported having minimal or no PPM programs (Table 5). For the remaining HBCs, the percentage of i ncident cases covered by PPM programs is often unclear. 17 Based on WHO and stakeholder estimates, we calculated that PPM programs involve over 500 physicians in only Cambodia, India, Indonesia, Pakistan and the Philippines, detect 22% or less of the private sector in all but Kenya, Myanmar, and the Philippines, and leave 29% or more of a country's total incident TB cases being treated in the private sector without the benefi t of PPM in 6 or more HBCs (Table 5) .
Early adoption by the private sector
Stakeholders noted that practices in the private sector, although much less uniform, have often preceded the process of public regimen change, especially if the NTP resists regimen change for a long time. (Nonrecommended practices may also be adopted by the private sector, but this study focused on WHO and NTP guidelines.) Past examples mentioned by stakeholders included: adoption of FDCs in the Philippines and Viet Nam; the daily continuation phase in Bangladesh; and the changes from an 8-to a 6-month regimen in Kenya and Uganda. Certain private sector practices may also predict future changes, as they mimic the global consensus more than the current national guidelines (e.g., the RHZE intensive phase in Viet Nam, 6-month regimen in Pakistan and Viet Nam, and daily dosing in India, estimated by one stakeholder to be practiced by ~40% of private practitioners in India). Stakeholders believed that regimen change 'should' occur fi rst in the public sector (54/59 responses) due to the public sector's greater adherence to standard regimens. But they acknowledged that change may be more likely to occur fi rst in the private sector. Private physicians reportedly want to offer new treatments to attract patients; this may lead them to seek out change (Indonesia, Philippines, and Viet Nam) and sometimes oppose a public sector regimen change so that the private sector retains its edge (China, Kenya). Early adoption in the private sector may be even more likely with a new, relatively expensive TB drug, as at least some private patients can pay (China, Indonesia, Philippines, and Viet Nam). Stakeholders in Indonesia and Pakistan noted that the private sector may also be a major audience for any new MDR-TB drugs as, according to them, currently the private sector bears most of the burden of this treatment.
Within the 17 HBCs responding to the relevant question, regimen choice in the private sector is most strongly infl uenced by medical associations (mentioned in 11 HBCs), drug companies and their representatives (10 HBCs), specialists (4 HBCs), and social marketing programs (2 HBCs). NTPs and PPM programs were often mentioned as playing a minor role.
DISCUSSION
Any new TB regimen will enter a complex treatment environment that includes various fi rst-line regimens, retreatment regimens, MDR-TB regimens, pediatric regimens, extra-pulmonary regimens, fi xed-dose combinations, patient kits, weight bands, and diagnostic and DST protocols. The potential impacts of a new regimen across all of these factors must be considered. To form a basis for this analysis, we outline here the current treatment landscape and the implications for future TB regimen change. Some of these data were verifi able (e.g., current regimens in guidelines), other questions elicited consistent answers (e.g., extent of DST), while private sector size was, in the absence of new data collection mechanisms, an estimate. In sum, however, we believe these data provide a valuable overview of the current treatment landscape.
Regimens and their use
The most basic component of the current treatment landscape is the fi rst-line regimen. Convergence of HBC Category I regimens towards a single standard (2HRZE/4RH, with dosing 7 days a week) will make the assimilation of Phase III clinical trial results easier, as this regimen matches the control arm used in these trials. This convergence is consistent with movement in WHO guidelines from a list of equal options 20 to a clear preference for a single Category I regimen 5, 6 based on an improved evidence base. 4 Where known, 'daily treatment' usually means 7 days a week. Thus, TB drug developers will probably not need to provide evidence of the effi cacy of 5-day dosing to accommodate NTP demands.
Under WHO guidelines, all current fi rst-line TB drugs are weight banded. This is thought to be necessary for at least some of the drugs to keep them within acceptable limits of effi cacy and toxicity, and its uniform application eases the design of FDCs. We found, however, that the implementation of weight banding is variable. Of note, weight banding is not necessary for many of the new TB drugs currently being tested (i.e., the same dose can be given to all adult patients). Building on previous analyses, 21 stakeholders could ideally reach a consensus on how many adult weight bands are necessary for new regimens. Initially, new regimens may be a more complex mix of weight banded and non-weight banded drugs, but truly novel regimens may not require weight banding.
These analyses will have important implications for the development of new FDCs. With FDCs now widely adopted (in excess of previous reports 17 ), their presence in new regimens is expected. 1 Development of new FDCs takes time and resources. Thus, the introduction of a completely novel fi rst-line TB drug may result, at least initially, in the replacement of four-or even two-drug FDCs with loose pills, thus increasing the number of commodities to be handled and the chances that at least one will be subject to a stock-out.
Many countries in Asia have large private sectors for TB treatment. Based on Table 5 , private sectors in the HBCs may treat ~21% of the global TB burden, but only ~5% of the global burden is covered by PPM. In a more recent analysis, drug usage data in 10 HBCs yielded a relative ranking of private market size similar to that estimated by stakeholders. 22 However, for the more signifi cant private markets, their absolute size appears to be substantially greater than the stakeholder estimates, likely due to repeated treatments in the private and public sectors.
Stakeholders indicated that the private sector can act as an early adopter, although with the risk that providers will use treatment regimens of variable length and with low adherence, 23 resulting in a risk of increased drug resistance and poor treatment outcomes. The modest size of most PPM programs (documented previously 24 and in this study) suggests that, in most countries, the current PPM programs are unlikely to reduce this risk substantially. As new TB drugs move through development, expansion of PPM efforts and increasing implementation of the International Standards for Tuberculosis Care (ISTC) 25 via professional associations will be essential.
The costs and benefi ts of DOT and adherence
The WHO has recommended DOT for any intensive phase and for continuation phases that include rifampicin. 5 In many settings, however, and especially in the continuation phase, DOT goes no further than family supervision and may require only one visit to a health care center per month, as noted in this study. Thus, a 4-month regimen may save just two visits and only modestly reduce the burden on the health care system.
However, a 4-month regimen would result in other epidemiological 26, 27 and programmatic savings. It would reduce by one third the size of the caseload that must be monitored, followed for side-effects management, and traced for defaulters. Furthermore, many health care systems maintain other, more frequent forms of DOT (e.g., community-based DOT) and other adherence interventions (provider training, patient health education, reimbursement, peer support, defaulter tracing, attendance prompts, contracts, and removal of barriers at community and family levels). The expenses of providing these interventions in the fi nal 2 months of treatment warrant further investigation. This is not, however, an area where it is possible to generalize. Adherence approaches, and the partner organizations who implement them, vary widely even within a single country.
DST coverage and prospects for its expansion
The possible emergence of drug resistance has been a prominent concern during past regimen changes, resulting in signifi cant adoption delays. 11 This is of particular concern for a future fl uoroquinolonecontaining fi rst-line TB drug regimen. Fluoroquinolones are a mainstay of second-line drug treatment; they are used for major non-TB indications, and are widely available over the counter. This would greatly increase the challenges of managing their rational use.
Ensuring suffi cient use of DST for future determination of drug resistance, even for the existing fi rstline drugs, will not be easy. The baseline levels of DST use are low-only 4.7% of retreatment cases and 2% of new cases. 17 The current study confi rmed that existing fl uoroquinolone DST capacity is extremely limited and its use almost always restricted to cases of treatment failure or MDR-TB. Furthermore, insuffi cient DST in a background of rising MDR-TB was reportedly increasing the pressure for ad hoc addition of more drugs during fi rst-line treatment.
DST has been recommended and used primarily as a tool for surveillance 28 and regimen design 29 rather than treatment; it has therefore been targeted only at retreatment cases, as this is where trends in resistance development are fi rst seen. 30, 31 However, the availability of line-probe assays and GeneXpert ® , the formation of the Global Laboratory Initiative (GLI), the expanded populations being targeted for DST in new treatment guidelines, 6 and the aggressive plans for expansion of MDR-TB treatment have raised the prospect of a greatly increased level of DST for fi rst-line drugs. Indeed, DST capacity is already expanding. 19 Prior to introducing a fl uoroquinolone-containing fi rst-line regimen, decision makers would benefi t from an assessment of fl uoroquinolone resistance rates in treatment-naïve TB patients (which may require a dedicated initiative) and a realistic assessment of likely future DST coverage (for both fi rst-line drugs and fl uoroquinolones). To limit concerns about resistance, efforts to implement a fl uoroquinolone-containing regimen and build DST capacity should be linked geographically. Quality assurance efforts, 32 which are not considered in depth here, will also remain crucial. In fact, for the introduction of new TB drugs in general, a broad consideration of measures to protect the drugs from resistance development (DST, DOT, FDCs, and strict controls over drug quality and distribution) will be an important part of the decision process.
CONCLUSION
By considering the current health systems used for TB treatment, TB drug developers can prioritize products that are more likely to meet the needs of TB programs, physicians, and patients. The same analysis can also highlight areas of health systems strengthening that can be undertaken now to facilitate future regimen changes. Improvement of drug management, and expansion of PPM, DOT (and other adherence mechanisms), FDC use, and DST are all initiatives that have been highlighted as benefi ting the delivery of current treatment regimens. 19, 33 The case for these actions is only strengthened by considering their impact on the introduction of new TB regimens. Confl ict of interest statement: WAW, CC, HRI, EG and NRS were or are employed by the Global Alliance for TB Drug Development, whose activities are aimed at developing and making available new therapies for TB. NK and DL are employed by Management Sciences for Health, which provides technical assistance with drug management in many of the high burden countries.
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